We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
Read MoreHide Full Article
Key Takeaways
AbbVie's Skyrizi and Rinvoq sales rose 53% to $18.5B so far in 2025, fueling a strong post-Humira recovery.
Robust volume gains and expanding indications support AbbVie's momentum across key IBD markets.
AbbVie sees combined Skyrizi and Rinvoq sales topping $25B in 2025 and surpassing $31B by 2027.
AbbVie (ABBV - Free Report) is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company faced a major setback in 2023 when Humira lost U.S. exclusivity, AbbVie has since returned to robust growth, driven by the strong and accelerating sales trajectories of Skyrizi and Rinvoq.
Despite being only in the third year post-Humira LOE, sales of Skyrizi and Rinvoq have not only softened the impact but have also positioned AbbVie for a clear top-line rebound. The company successfully launched both drugs across Humira's major indications and a distinct new indication, atopic dermatitis. Skyrizi and Rinvoq have also demonstrated compelling head-to-head data against several novel therapies in clinical studies, giving them a competitive advantage.
So far this year, the combined sales of Skyrizi and Rinvoq have surged 53% year over year to $18.5 billion. This momentum is fueled by strong volume growth and continued market share gains across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). In its Q3 conference call, AbbVie noted that the two drugs together now command roughly half of the in-play CD market and nearly one-third of the UC market in the United States, underscoring strong physician adoption. Building on this strength, AbbVie expects combined sales of the two drugs to exceed $25 billion in 2025.
Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs’ growth. AbbVie expects to file a regulatory submission for Rinvoq for the alopecia areata indication before this year’s end. In addition, phase III data with Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected in 2026. AbbVie believes that the next wave of potential approvals in Rinvoq could contribute roughly $2 billion to peak-year sales for the product. By 2027, AbbVie expects combined sales of Skyrizi and Rinvoq to surpass $31 billion.
Apart from immunology, AbbVie has been expanding its presence in oncology and neuroscience. In recent years, the company has added Epkinly, Elahere and most recently, Emrelis, bringing its total oncology therapies to five. Growth in its neuroscience segment is also supported by increasing uptake of its migraine drugs, Ubrelvy and Qulipta.
ABBV’s Rivals in the Immunology Space
The targeted market is highly competitive. A key player in the immunology market is Johnson & Johnson (JNJ - Free Report) , which markets two blockbuster drugs — Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity earlier this year, J&J has shifted focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its portfolio in this therapeutic area. The Eli Lilly drug received FDA approval for the CD indication in January.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.31 times forward earnings compared to the industry's average of 16.91. The stock is trading above its five-year mean of 13.43.
Image Source: Zacks Investment Research
Movements in EPS estimates for 2025 and 2026 have been mixed in the past 30 days.
Image: Shutterstock
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
Key Takeaways
AbbVie (ABBV - Free Report) is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company faced a major setback in 2023 when Humira lost U.S. exclusivity, AbbVie has since returned to robust growth, driven by the strong and accelerating sales trajectories of Skyrizi and Rinvoq.
Despite being only in the third year post-Humira LOE, sales of Skyrizi and Rinvoq have not only softened the impact but have also positioned AbbVie for a clear top-line rebound. The company successfully launched both drugs across Humira's major indications and a distinct new indication, atopic dermatitis. Skyrizi and Rinvoq have also demonstrated compelling head-to-head data against several novel therapies in clinical studies, giving them a competitive advantage.
So far this year, the combined sales of Skyrizi and Rinvoq have surged 53% year over year to $18.5 billion. This momentum is fueled by strong volume growth and continued market share gains across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). In its Q3 conference call, AbbVie noted that the two drugs together now command roughly half of the in-play CD market and nearly one-third of the UC market in the United States, underscoring strong physician adoption. Building on this strength, AbbVie expects combined sales of the two drugs to exceed $25 billion in 2025.
Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs’ growth. AbbVie expects to file a regulatory submission for Rinvoq for the alopecia areata indication before this year’s end. In addition, phase III data with Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected in 2026. AbbVie believes that the next wave of potential approvals in Rinvoq could contribute roughly $2 billion to peak-year sales for the product. By 2027, AbbVie expects combined sales of Skyrizi and Rinvoq to surpass $31 billion.
Apart from immunology, AbbVie has been expanding its presence in oncology and neuroscience. In recent years, the company has added Epkinly, Elahere and most recently, Emrelis, bringing its total oncology therapies to five. Growth in its neuroscience segment is also supported by increasing uptake of its migraine drugs, Ubrelvy and Qulipta.
ABBV’s Rivals in the Immunology Space
The targeted market is highly competitive. A key player in the immunology market is Johnson & Johnson (JNJ - Free Report) , which markets two blockbuster drugs — Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity earlier this year, J&J has shifted focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its portfolio in this therapeutic area. The Eli Lilly drug received FDA approval for the CD indication in January.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.31 times forward earnings compared to the industry's average of 16.91. The stock is trading above its five-year mean of 13.43.
Image Source: Zacks Investment Research
Movements in EPS estimates for 2025 and 2026 have been mixed in the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.